Roivant Sciences Ltd.
ROIVNASDAQHealthcare● Active
$28.58
$-0.95(-3.22%)
Market Cap$20.6B
P/E Ratio—
52W High$32.793
52W Low$10.705
Roivant Sciences Ltd. (ROIV) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ROIV · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 20, 2026EPS Actual
-$0.28
Est. -$0.29 · +3.5%
Revenue
$0.00B
Est. $0.00B · -26.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 20, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue🔥 6-Quarter EPS Beat Streak
ROIV reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.33 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 20, 2026 | -$0.29 | -$0.28 | +3.5% | $0.00B | $0.00B | -26.2% |
| ▲ Q1 FY2026 | Feb 6, 2026 | -$0.30 | -$0.24 | +19.9% | $0.00B | $0.01B | -60.6% |
| ▲ Q4 FY2025 | Nov 10, 2025 | -$0.32 | -$0.28 | +12.4% | $0.00B | $0.01B | -72.0% |
| ▲ Q3 FY2025 | Aug 11, 2025 | -$0.25 | -$0.18 | +27.9% | $0.00B | $0.01B | -70.3% |
| ▲ Q2 FY2025 | May 29, 2025 | -$0.26 | -$0.22 | +16.5% | $0.01B | $0.05B | -86.0% |
| ▲ Q1 FY2025 | Feb 10, 2025 | -$0.24 | -$0.13 | +45.8% | $0.01B | $0.06B | -85.5% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.25 | -$0.29 | -17.4% | $0.00B | $0.05B | -90.3% |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.33
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 20, 2026Beat
EPS Actual
-$0.28
EPS Est.
-$0.29
EPS Surpr.
+3.5%
Revenue
$0.00B
Q1 FY2026
Feb 6, 2026Beat
EPS Actual
-$0.24
EPS Est.
-$0.30
EPS Surpr.
+19.9%
Revenue
$0.00B
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
-$0.28
EPS Est.
-$0.32
EPS Surpr.
+12.4%
Revenue
$0.00B
Q3 FY2025
Aug 11, 2025Beat
EPS Actual
-$0.18
EPS Est.
-$0.25
EPS Surpr.
+27.9%
Revenue
$0.00B
Q2 FY2025
May 29, 2025Beat
EPS Actual
-$0.22
EPS Est.
-$0.26
EPS Surpr.
+16.5%
Revenue
$0.01B
Q1 FY2025
Feb 10, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.24
EPS Surpr.
+45.8%
Revenue
$0.01B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.29
EPS Est.
-$0.25
EPS Surpr.
-17.4%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2028 | $-0.44 | $-0.25 | $-0.13 | 1 |
| Q4 FY2027 | $-0.48 | $-0.28 | $-0.14 | 1 |
| Q3 FY2027 | $-0.52 | $-0.29 | $-0.15 | 1 |
| Q2 FY2027 | $-0.53 | $-0.30 | $-0.15 | 1 |
| Q1 FY2027 | $-0.54 | $-0.31 | $-0.15 | 1 |
| Q4 FY2026 | $-0.55 | $-0.31 | $-0.16 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2028 | $0.1B | $0.1B | $0.2B | 2 |
| Q4 FY2027 | $0.1B | $0.1B | $0.2B | 3 |
| Q3 FY2027 | $0.0B | $0.1B | $0.1B | 3 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q1 FY2027 | $0.0B | $0.1B | $0.1B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 20, 2026 | +3.5% | $28.21 | $32.41 | +14.89% |
| ▲ Q1 FY2026 | Feb 6, 2026 | +19.9% | $21.14 | $25.82 | +22.14% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +12.4% | $20.62 | $21.17 | +2.67% |
| ▲ Q3 FY2025 | Aug 11, 2025 | +27.9% | $11.49 | $11.17 | -2.79% |
| ▲ Q2 FY2025 | May 29, 2025 | +16.5% | $10.62 | $11.30 | +6.40% |
| ▲ Q1 FY2025 | Feb 10, 2025 | +45.8% | $10.89 | $10.79 | -0.92% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -17.4% | $11.81 | $11.64 | -1.44% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +26.0% | $10.17 | $10.85 | +6.69% |
Q2 FY2026+14.89%
Report Date
May 20, 2026
EPS Beat/Miss
+3.5%
Price Before
$28.21
Price After
$32.41
Q1 FY2026+22.14%
Report Date
Feb 6, 2026
EPS Beat/Miss
+19.9%
Price Before
$21.14
Price After
$25.82
Q4 FY2025+2.67%
Report Date
Nov 10, 2025
EPS Beat/Miss
+12.4%
Price Before
$20.62
Price After
$21.17
Q3 FY2025-2.79%
Report Date
Aug 11, 2025
EPS Beat/Miss
+27.9%
Price Before
$11.49
Price After
$11.17
Q2 FY2025+6.40%
Report Date
May 29, 2025
EPS Beat/Miss
+16.5%
Price Before
$10.62
Price After
$11.30
Q1 FY2025-0.92%
Report Date
Feb 10, 2025
EPS Beat/Miss
+45.8%
Price Before
$10.89
Price After
$10.79
Q4 FY2024-1.44%
Report Date
Nov 12, 2024
EPS Beat/Miss
-17.4%
Price Before
$11.81
Price After
$11.64
Q3 FY2024+6.69%
Report Date
Aug 8, 2024
EPS Beat/Miss
+26.0%
Price Before
$10.17
Price After
$10.85
Avg Beat Reaction+7.01%
Avg Miss Reaction-1.44%
Beat Rate7 / 8 quarters
Largest Move+22.14% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ROIV ends December
Roivant Sciences Ltd. (ROIV) most recently reported earnings on May 20, 2026 for Q2 FY2026, posting EPS of $-0.28 — beating the analyst consensus of $-0.29 by +3.5%. ROIV has beaten EPS estimates for 6 consecutive quarters. The next ROIV earnings date is expected around September 1, 2026.
Each quarter, investors track ROIV earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ROIV revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ROIV's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ROIV earnings · 5 questionsRoivant Sciences Ltd.'s next earnings report is expected around September 1, 2026. ROIV typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ROIV historically reports after market close (AMC).
ROIV earnings datewhen is ROIV earningsROIV next earnings datewhen does ROIV report earningsROIV earnings calendar
▸ Source: FMP · Roivant Sciences Ltd. SEC filings · US GAAP · Roivant Sciences Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026